

## Fluorination of 5'-Deoxy-5'-(methylthio)adenosine with Xenon Difluoride provides an Expedient Synthesis of (Fluoromethylthio)adenosine

Georges Guillerm\* and Marie Gâtel

Laboratoire de Chimie Bioorganique associé au CNRS, Université de Reims–Champagne–Ardenne, UFR Sciences BP 347 51062 Reims Cedex—France

Fluorination of 5'-deoxy-5'-(fluoromethylthio)adenosine derivatives with xenon difluoride at  $-60\text{ }^{\circ}\text{C}$  in dichloromethane occurs exclusively at the methylthio position to provide a simple and efficient preparation of 5'-deoxy-5'-(fluoromethylthio)adenosine.

5'-Deoxy-5'-(methylthio)adenosine (MTA) is an important product of *S*-adenosylmethionine metabolism formed as a by-product during biosynthesis of the polyamines, spermidine and spermine.<sup>1</sup> Interest in MTA and its analogues has been stimulated since studies have revealed that MTA is a fundamental component of the complex system responsible for cell growth and proliferation.<sup>2,3</sup> Consequently, the inhibitors of the enzymes involved in MTA catabolism, MTA phosphorylase in mammal cells<sup>4</sup> and MTA nucleosidase in many microorganisms,<sup>5-7</sup> have been examined as potential chemotherapeutic agents.<sup>8-10</sup>

Recently, 5'-deoxy-5'-(fluoromethylthio)adenosine (MFMTA) has been synthesized and evaluated as inhibitor of MTA phosphorylase and its antiproliferative effect tested,<sup>11</sup> but its biological activity has not been fully explored yet. Our interest in MTA nucleosidase<sup>12</sup> led us to examine the effect of MFMTA on the activity of a typical bacterial enzyme and explore a new route to MFMTA since no convenient preparative method is currently available.


MFMTA has been prepared recently<sup>11,13,14</sup> in low yield (<10%) using the general procedure of McCarthy.<sup>15</sup> This method gave a regioisomeric mixture, of 5'-deoxy-5'-(fluoromethylthio)adenosine and 5'-fluoro-5'-*S*-(methylthio)adenosine, whose separation is tedious. The finding that  $\text{XeF}_2$  is suitable for  $\alpha$ -fluorination of a sulfide<sup>16,17</sup> suggested that it might be useful for the preparation of MFMTA.

Herein we report a simple and convenient method for the preparation of MFMTA by means of direct and regioselective fluorination of suitable protected derivatives of MTA. Protecting groups for **2a–b** were chosen to avoid acidic conditions during their removal since  $\alpha$ -fluoro thioethers were reported to be unstable under these conditions.<sup>11,18</sup> As Scheme 1 shows, the protected MTAs **2a–b** were subjected to monofluorination, exclusively at the methylthio position with xenon difluoride. The only minor side-product formed was 5'-deoxy-5'-methylthioadenosine sulfoxide **4a** or **4b** which could result from hydrolysis of the possible corresponding sulfur(IV) difluoride intermediate, as has been proposed in the mechanism of  $\alpha$ -fluorination of alkyl sulfides.<sup>16</sup>

After the optimal reaction conditions had been achieved, the reaction yielded the desired fluorinated nucleosides **3a–b** in isolated yields of 75 and 70% as described below.

Separation of **3a**, **4a** and **3b**, **4b** was performed by flash chromatography on silica gel. Removal of protecting groups was achieved in both cases in nearly quantitative yield to give **5**.

The availability of MFMTA by this procedure will allow the complete evaluation of its biological activity as a potential inhibitor of MTA nucleosidases from various microorganisms. Our preliminary investigations in this field showed that MFMTA inhibits 5'-methylthioadenosine nucleosidase [E.C. 3.2.2.9] from *E. coli* and, furthermore, it serves as substrate for the enzyme.



**Scheme 1** Reagents and conditions: i, BzCl, pyridine (16 h, room temp., 85%); ii,  $\text{Ac}_2\text{O}$ , DMAP and  $\text{NEt}_3$ ,  $\text{CH}_3\text{CN}$  (1 h, room temp., 78%); iii,  $\text{XeF}_2$  (1.3 equiv.),  $\text{CH}_2\text{Cl}_2$  ( $-60\text{ }^{\circ}\text{C}$ , 6 h); iv,  $\text{Na}_2\text{CO}_3$  (2 equiv.), MeOH (15 h, room temp.)

### Experimental

**General Procedure for Fluorination with  $\text{XeF}_2$ .**—Compound **2a** or **2b** (1 mmol) in  $\text{CH}_2\text{Cl}_2$  (1  $\text{cm}^3$ ) was injected under argon into a stirred solution of  $\text{XeF}_2$  (1.3 mmol) in  $\text{CH}_2\text{Cl}_2$  (4  $\text{cm}^3$ ) at  $-60\text{ }^{\circ}\text{C}$ . The mixture was stirred at  $-60\text{ }^{\circ}\text{C}$  for 6 h after which hexamethyldisilazane (1.3 mmol) in  $\text{CH}_2\text{Cl}_2$  (1  $\text{cm}^3$ ) was added to it to quench the HF formed. Volatile material was removed under reduced pressure to leave a residue which was analysed by NMR. This showed the absence of starting material and the presence of the fluorinated derivatives **3a** or **3b**, formed with <5% of their corresponding sulfoxides **4a** or **4b** (identified by their known NMR spectrum).<sup>13,14</sup> Purification of **3a** or **3b** was

achieved by flash chromatography on silica gel using ethyl acetate-hexane as eluting solvent (1:1, v/v) for **3a** and (4:1, v/v) for **3b**.

Deprotection of the hydroxy and amino groups in **3a** and **3b** was achieved by treatment with  $\text{Na}_2\text{CO}_3$  (2 mol equiv.) in MeOH for 15 h at room temperature. The methanolic solution was passed through a short column of Dowex resin (AG3, X4-OH<sup>-</sup>) extensively washed with MeOH. The methanolic resulting solution was neutralised with (AG 50 WX8-H<sup>+</sup>) and evaporated to afford pure **5** in 95% yield.

**N<sup>6</sup>,N<sup>6</sup>-Dibenzoyl-2',3'-O-dibenzoyl-5'-deoxy-5'-fluoromethylthioadenosine 3a.** M.p. 132 °C;  $\delta_{\text{H}}$ (250 MHz,  $\text{CDCl}_3$ , J/Hz) 3.3 (m, 2 H, 5'- and 5''-H), 4.7 (m, 1 H, 4'-H,  $J_{4',5'} = J_{4',5''} = 4.5$ ), 5.5 (d, 2 H,  $\text{CH}_2\text{F}$ ,  $J_{\text{H,F}} = 51$ ), 6 (t, 1 H, 3'-H,  $J_{3',4'} = 5$ ), 6.3 (t, 1 H, 2'-H,  $J_{2',3'} = 5.2$ ), 6.4 (d, 1 H, 1'-H,  $J_{1',2'} = 5$ ), 7 and 7.7 (m, 20 H, PhCO) and 8.7 and 8.3 (2 s, 2 H, 2- and 8-H);  $\delta_{\text{F}}$ (250 MHz,  $\text{CDCl}_3$ , J/Hz) -183 (t, 1 F,  $J_{\text{H,F}} = 51$ );  $m/z$  (DCI/ $\text{NH}_3$ ) 732 (M, H)<sup>+</sup>;  $[\alpha]_{\text{D}}^{20} 86.6$  (c 0.86 in  $\text{CHCl}_3$ ).

**2',3'-O-Diacetyl-5'-deoxy-5'-fluoromethylthioadenosine 3b.** M.p. 163 °C;  $\delta_{\text{H}}$ (250 MHz,  $\text{CDCl}_3$ , J/Hz) 2 and 2.1 (2 s, 6 H,  $\text{CH}_3\text{CO}$ ), 3.2 (m, 2 H, 5'- and 5''-H), 4.4 (m, 1 H, 4'-H,  $J_{4',5'} = J_{4',3'} = 5.7$ ), 5.5 (d, 2 H,  $\text{CH}_2\text{F}$ ,  $J_{\text{H,F}} = 52$ ), 5.6 (dd, 1 H, 3'-H,  $J_{2',3'} = 4.5$ ), 5.9 (s large, 2 H,  $\text{NH}_2$ ), 6.01 (dd, 1 H, 2'-H), 6.13 (d, 1 H, 1'-H,  $J_{1',2'} = 5.7$ ) and 7.9 and 8.35 (2 s, 2 H, 2- and 8-H);  $\delta_{\text{F}}$ (250 MHz,  $\text{CDCl}_3$ , J/Hz) -183 (t, 1 F,  $J_{\text{H,F}} = 52$ );  $[\alpha]_{\text{D}}^{20} -75.6$  (c 1.54 in  $\text{CHCl}_3$ ).

**5'-Deoxy-5'-fluoromethylthioadenosine 5.** M.p. 196 °C (decomp.);  $\delta_{\text{H}}$ (250 MHz,  $\text{CDCl}_3\text{-CD}_3\text{OD}$ ) 3.07 (m, 2 H, 5'- and 5''-H,  $J_{5',5''} = 14$ ,  $J_{4',5'} = J_{4',5''} = 4.6$ ,  $J_{5',\text{F}} = J_{5'',\text{F}} = 2$ ), 4.2 (m, 2 H, 3'- and 4'-H), 4.6 (t, 1 H, 2'-H,  $J_{2',3'} = 4.5$ ), 5.5 (m, 2 H,  $\text{CH}_2\text{F}$ ,  $J_{\text{H,F}} = 52$ ), 5.9 (d, 1 H, 1'-H,  $J_{1',2'} = 4.5$ ) and 8.05 and 8.1 (2 s, 2 H, 2- and 8-H);  $\delta_{\text{F}}$ (250 MHz,  $\text{CDCl}_3\text{-CD}_3\text{OD}$ ) -183 (t, 1 F,  $J_{\text{H,F}} = 52$ );  $m/z$  (DCI/ $\text{NH}_3$ ) 316 (M, H)<sup>+</sup>.

## References

- 1 A. J. Ferro, in *Transmethylation*, Usdin, eds. E. Borchardt, R. T. Borchardt and C. R. Creveling, 1979, Elsevier/North Holland, New York.
- 2 V. Zappia and A. E. Pegg, in *Advances in Experimental Medicine and Biology*, eds. V. Zappia and A. E. Pegg, Plenum Press, New York, 1988, vol. 250.
- 3 H. G. Williams-Ashman, J. Seidenfeld and P. Galletti, *Biochem. Pharmacol.*, 1982, **31**, 277.
- 4 A. E. Pegg and H. G. Williams-Ashman, *Biochem. J.*, 1969, **115**, 241.
- 5 J. A. Duerre, *J. Biol. Chem.*, 1962, **237**, 3737.
- 6 A. J. Ferro, A. Barrett and S. K. Shapiro, *Biochem. Biophys. Acta*, 1976, **438**, 487.
- 7 A. B. Guranowski, P. K. Chiang and G. L. Cantoni, *Eur. J. Biochem.*, 1981, **114**, 293.
- 8 S. Nishikawa, A. Ueno, H. Inoue and Y. Takeda, *J. Cellular Physiol.*, 1987, **133**, 372.
- 9 M. E. Houston, D. L. Vanderjagt and J. F. Honek, *Bioorg. Med. Chem. Lett.*, 1992, **1**, 623.
- 10 F. Della Regione, M. Porcelli, M. Carteni Farina, V. Zappia and A. E. Pegg, *Biochem. J.*, 1985, **335**, 232.
- 11 J. R. Sufrin, A. J. Spiess, D. L. Kramer, P. R. Libby and C. W. Porter, *J. Med. Chem.*, 1989, **32**, 997.
- 12 G. Guillermin, M. Varkados, S. Auvin and F. Le Goffic, *Tetrahedron Lett.*, 1987, **28**, 535.
- 13 M. T. Robins and S. F. Wnuk, *Tetrahedron Lett.*, 1988, **29**, 5729.
- 14 J. R. Sufrin, A. J. Spiess and V. Alks, *J. Fluorine Chem.*, 1990, **49**, 177.
- 15 J. R. McCarthy, N. P. Peet, M. E. Le Tourneau and M. Inbasekaran, *J. Am. Chem. Soc.*, 1985, **107**, 735.
- 16 R. K. Marat and A. F. Janzen, *Can. J. Chem.*, 1977, **55**, 3031.
- 17 A. F. Janzen, P. M. C. Wang and A. E. Lemire, *J. Fluorine Chem.*, 1983, **22**, 577.
- 18 M. E. Houston and J. F. Honek, *J. Chem. Soc., Chem. Commun.*, 1989, **12**, 761.

Paper 3/06958C

Received 22nd November 1993

Accepted 23rd November 1993